ViiV – which is majority-owned by GSK – has said Cabenuva is central to its plans to grow its HIV sales over the next five years alongside long-acting injectable Apretude (cabotegravir), an ...

and a contribution by recently-launched long-acting injectable Cabenuva (cabotegravir). On the downside, GSK's COVID-19 therapy Xevudy (sotrovimab) saw a slump in demand, with sales falling to £ ...

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and treatment, with Apretude showing zero HIV acquisitions and Cabenuva ...

That equation led Vyvgart, argenx’s treatment for generalized myasthenia gravis (gMG), to take the top spot, with an overall score of 3.9. Cabenuva, GSK’s long-acting HIV treatment ...

HIV sales rose 14% driven by strong demand and increased market share for oral two-drug regimens, Dovato and Juluca, and long-acting regimens like Cabenuva and Apretude. GSK generates the majority ...

About Cabenuva (cabotegravir + rilpivirine ... is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in ...

LONDON, March 12, 2025--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer ... data were also presented for Cabenuva, the only approved ...

LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and ... physician experience we have with Cabenuva and pioneering the next generation ...